Bank Of America Corp Medicinova Inc Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Medicinova Inc stock. As of the latest transaction made, Bank Of America Corp holds 118,661 shares of MNOV stock, worth $240,881. This represents 0.0% of its overall portfolio holdings.

Number of Shares

118,661

Previous 148,459 20.07%

Holding current value

$240,881

Previous $215,000 20.93%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.28 - $1.57 $38,141 - $46,782	-29,798 Reduced 20.07%	118,661 $170,000
Q1 2024 May 15, 2024	SELL	$1.28 - $1.65 $24,960 - $32,175	-19,500 Reduced 11.61%	148,459 $215,000
Q4 2023 Feb 14, 2024	BUY	$1.38 - $2.06 $82,110 - $122,570	59,500 Added 54.86%	167,959 $251,000
Q2 2023 Aug 14, 2023	SELL	$2.09 - $2.43 $54,130 - $62,937	-25,900 Reduced 19.28%	108,459 $249,000
Q1 2023 May 12, 2023	SELL	$1.95 - $2.54 $83,655 - $108,966	-42,900 Reduced 24.2%	134,359 $290,000
Q4 2022 Feb 10, 2023	BUY	$1.97 - $2.66 $44,340 - $59,871	22,508 Added 14.54%	177,259 $363,000
Q3 2022 Nov 14, 2022	SELL	$2.1 - $2.6 $9,870 - $12,220	-4,700 Reduced 2.95%	154,751 $336,000
Q2 2022 Aug 12, 2022	SELL	$2.31 - $3.14 $46,260 - $62,881	-20,026 Reduced 11.16%	159,451 $403,000
Q1 2022 May 16, 2022	SELL	$2.19 - $2.81 $70,257 - $90,147	-32,081 Reduced 15.16%	179,477 $480,000
Q4 2021 Feb 08, 2022	BUY	$2.61 - $4.42 $175,167 - $296,643	67,114 Added 46.46%	211,558 $567,000
Q3 2021 Nov 15, 2021	SELL	$3.4 - $4.24 $82,684 - $103,112	-24,319 Reduced 14.41%	144,444 $548,000
Q2 2021 Sep 13, 2021	BUY	$3.76 - $5.14 $634,548 - $867,441	168,763 New	168,763 $717,000

Others Institutions Holding MNOV

# of Institutions

Shares Held

4.69M

Call Options Held

7.2K

Put Options Held

3.8K

View Full List

About MEDICINOVA INC

Ticker MNOV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,046,200
Market Cap $99.6M
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...

More about MNOV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Medicinova Inc Transaction History